Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening

Main|Search|PHGKB


Last Posted: Jun 29, 2017

---

• Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening  
  Kasper Aalbæk Kjærgaard, et al, JAHA June 26, 2017
• Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia  
  PN Hopkins, JAHA, June 26, 2017
• Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.  
  Kjærgaard Kasper Aalbæk et al. Journal of the American Heart Association 2017 Jun 6(6)
• PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.  
  Baum Seth J et al. Clinical cardiology 2017 Apr 40(4) 243-254
• Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia.  
  Hopkins Paul N et al. Journal of the American Heart Association 2017 Jun 6(6)
• Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.  
  Pecin Ivan et al. European journal of preventive cardiology 2017 Jan 2047487317717346
• Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.  
  Wang Jian et al. Arteriosclerosis, thrombosis, and vascular biology 2016 Dec 36(12) 2439-2445
• Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.  
  Sharifi Mahtab et al. Atherosclerosis 2017 May
• When do paediatric patients with familial hypercholesterolemia need statin therapy?  
  Hennig Matylda et al. Developmental period medicine 2017 21(1) 43-50
• How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?  
  Masana Luis et al. Atherosclerosis 2017 May 262107-112
• Recent advances in genetic testing for familial hypercholesterolemia.  
  Iacocca Michael A et al. Expert review of molecular diagnostics 2017 May
• The rationale and design of the national familial hypercholesterolemia registries in Turkey: A-HIT1 and A-HIT2 studies.  
  Kayikçioglu Meral et al. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017 Apr 45(3) 261-267
• Transitioning from pediatric to adult health care with familial hypercholesterolemia: Listening to young adult and parent voices.  
  Sliwinski Samantha K et al. Journal of clinical lipidology 11(1) 147-159
• New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.  
  Ellis Katrina L et al. European journal of preventive cardiology 2017 Jan 2047487317708890
• Can we afford not to screen for FH?  
  RM Stoekenbroek et al, Europ Heart Journal, April 2017
• Nine paths to PCSK9 inhibition  
  A Mullard, Nature Rev Drug Discovery, April 2017

more